DRUG
Ganirelix acetate
Ganirelix acetate: .25 ml/day by subcutaneous injection
Status
Completed
Phase
Phase 2
Enrollment
109
Locations
1
Results
Posted
Publications
0
Study summary
This study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. Orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.
In this study we are interested in determining the impact of female reproductive hormones (estrogen and progesterone) on orthostatic tolerance (described above) so we administer these hormones to participants. We also test participants' orthostatic tolerance in our laboratory and use this information to place subjects into groups.
Interventions
DRUG
Ganirelix acetate: .25 ml/day by subcutaneous injection
DRUG
17 beta estradiol: 0.2 mg/day (patches)
DRUG
progesterone, 200 mg day-1 oral
Timeline
First posted
Jun 30, 2010
Study start
Feb 2006
Primary completion
Dec 2012
Study completion
May 2013
Results posted
Jan 30, 2017
Registry updated
Dec 13, 2018
Outcomes
Orthostatic Tolerance
Time frame · 2 months
We used a measure called cumulative stress index to determine orthostatic tolerance, which is the amount of time at a level of negative pressure each subject can maintain before feeling as if she is going to pass out. This is calculated by multiplying the pressure in mm Hg by the time in min.
Baroreceptor Function
Time frame · 2 months
This is a measure of how the body responds to changes in pressure induced by changes in position such as sitting, lying standing. The pressure changes are induced by gravity. The measurement described below to assess baroreceptor function is units of change in forearm vascular resistance for a given change in lower body negative pressure. This allows us to determine how good the body is at sending signals to the periphery to respond to postural changes. Baroreflex sensitivity is defined as the change in interbeat interval (IBI) in milliseconds per unit change in BP. For example, when the BP rises by 10 mmHg and IBI increases by 100 ms, BRS would be 100/10 = 10 ms/mmHg.
Skin Microvascular Responses
Time frame · 2 months
Changes in blood flow in the small vessel in the skin are measured in response to sequential heat and drug stimulation. It is measured in volts, and then corrected for a maximum level and expressed as "% max." This is measured with a Laser Doppler probes, which measures volts.
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Healthy, English-speaking non-smoking women age 18- 34 with regular menses Exclusion Criteria: * Gynecologic: 1. current or past estrogen-dependent neoplasia, 2. unexplained vaginal bleeding, 3. history of uterine fibroids, 4. current pregnancy, 5. known or suspected breast or uterine cancer, 6. partial or complete hysterectomy * Cardiac: 1. myocardial infarction, ventricle tachycardia or fibrillation, 2. angina, 3. valvular disease, 4. congestive heart failure, orthopnea, paroxysmal nocturnal dyspnea, 5. current arrhythmias, 6. prosthetic valves * Pulmonary: 1. current cigarette smokers, or pipe or cigar smokers, 2. chronic obstructive pulmonary disease, 3. adult asthma, 4. dyspnea on exertion, 5. current bronchitis, pneumonia, or tuberculosis, 6. lung carcinoma, 7. pulmonary embolus, recent * Vascular: 1. claudication or history of peripheral vascular disease, 2. abdominal or thoracic aortic aneurysm, or repair of same, 3. cerebral aneurysm, vascular malformations, 4. hypertension, systolic or diastolic, or strong family history of hypertension * Gastrointestinal: 1. GI malignancy, 2. hepatitis, current, 3. splenomegaly from any cause, 4. Cholecystitis, 5. current diverticulosis or diverticulitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease, 6. previous gastrointestinal surgery * Infectious Disease: any intercurrent infection * Hematologic/Oncologic: 1. receiving chemotherapy or radiation therapy, 2. any metastatic malignancy, 3. anemia (hematocrit \< 35), 4. thrombocytopenia or thrombocytosis, 5. neutropenia, 6. hematologic malignancy, 7. bleeding dyscrasia * Neurologic: 1. history of cerebral vascular accident with any neurologic sequels, 2. uncontrolled seizures (e.g. more than 1 seizure/year), 3. transient ischemic attacks, 4. dementia, 5. neurologic conditions producing dyscoordination, peripheral neuropathy, or myopathy, 6. severe migraine headaches * Endocrine: 1. diabetes mellitus, 2. any untreated endocrinopathy * Renal: 1. chronic renal disease, 2. any history of renal disease or impairment, 3. current urinary tract infection * Musculoskeletal: 1. inflammatory arthritis history (e.g., rheumatoid, psoriatic, Reiters), 2. any history of pathologic fractures, including vertebral compression fractures * Pharmacologic: 1. any illegal drug use, 2. alcohol use greater than an average of 4 oz/day over 30 days, 3. coumadin or heparin use, 4. current systemic antifungal use
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
John B. Pierce Laboratory
New Haven, Connecticut, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
University of Delaware · Estrogen · Premenopause
Phase 4
Recruiting
30
2026-07
ART Fertility Clinics LLC · Healthy
Not applicable
Not yet recruiting
20
2026-05
Fundación Santiago Dexeus Font · Infertility
Phase 4
Completed
110
2026-04
Instituto Bernabeu · IVF
Phase 4
Completed
150
2026-03
Hanoi Medical University · Infertility (IVF Patients) · Embryo Morphokinetics
Not applicable
Recruiting
148
2026-02
University Hospital, Ghent · Ovarian Stimulation · Quality of Life
Phase 4
Recruiting
60
2025-12
Tam Anh TP. Ho Chi Minh General Hospital · Diminished Ovarian Reserve
Not applicable
Recruiting
730
2025-12
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.